Literature DB >> 25646853

Whole genome sequencing reveals a de novo SHANK3 mutation in familial autism spectrum disorder.

Sergio I Nemirovsky1, Marta Córdoba2, Jonathan J Zaiat1, Sabrina P Completa1, Patricia A Vega2, Dolores González-Morón2, Nancy M Medina2, Mónica Fabbro3, Soledad Romero3, Bianca Brun3, Santiago Revale3, María Florencia Ogara4, Adali Pecci4, Marcelo Marti5, Martin Vazquez3, Adrián Turjanski5, Marcelo A Kauffman2.   

Abstract

INTRODUCTION: Clinical genomics promise to be especially suitable for the study of etiologically heterogeneous conditions such as Autism Spectrum Disorder (ASD). Here we present three siblings with ASD where we evaluated the usefulness of Whole Genome Sequencing (WGS) for the diagnostic approach to ASD.
METHODS: We identified a family segregating ASD in three siblings with an unidentified cause. We performed WGS in the three probands and used a state-of-the-art comprehensive bioinformatic analysis pipeline and prioritized the identified variants located in genes likely to be related to ASD. We validated the finding by Sanger sequencing in the probands and their parents.
RESULTS: Three male siblings presented a syndrome characterized by severe intellectual disability, absence of language, autism spectrum symptoms and epilepsy with negative family history for mental retardation, language disorders, ASD or other psychiatric disorders. We found germline mosaicism for a heterozygous deletion of a cytosine in the exon 21 of the SHANK3 gene, resulting in a missense sequence of 5 codons followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6).
CONCLUSIONS: We reported an infrequent form of familial ASD where WGS proved useful in the clinic. We identified a mutation in SHANK3 that underscores its relevance in Autism Spectrum Disorder.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25646853      PMCID: PMC4315573          DOI: 10.1371/journal.pone.0116358

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Autism spectrum disorder (ASD) is a common cause of early disability, affecting about 1% of the population. It is characterized by impairments in social interaction and communication, as well as by repetitive and restricted behaviors [1]. ASD is etiologically heterogeneous, with hundreds of highly penetrant genetic aberrations involved as causative factors. Among them, SHANK3 haploinsufficiency has been identified in about 0.5% of subjects with ASD. However, few familial ASD cases caused by mutations in SHANK3 have been identified [2]. Here we present three siblings with ASD where Whole Genome Sequencing (WGS), identified germline mosaicism for a new mutation in SHANK3.

Methods

Study participants

The Ethics Committee of Hospital Ramos Mejía in Buenos Aires, Argentina approved this study. Written informed consents were obtained from the parents of the probands. Clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The parents of the individuals described in this manuscript gave written informed consent to publish these case details. DNA sequencing data remained stored in a secure internal database, and is available upon request to researchers wishing to use them for research purposes only. Clinical evaluations were performed at the Neurogenetics Unit from Hospital Ramos Mejía.

Genome sequence data generation

Genomic DNA was isolated from peripheral blood and sequenced using 101 base-pair paired-end reversible terminator massively parallel sequencing on an Illumina Hiseq 1500 instrument at INDEAR (Rosario, Argentina), following sequencing library preparation in agreement to standard Illumina protocols. Median fragment length of the libraries was 294 bp. A total of 334.1 Gb with quality equal or more than Q30 was produced for the three genomes. Specifically, 575,427,640 paired-end reads were produced for proband 1 (35.5X coverage), 603,002,568 paired-end reads were produced for proband 2 (37.18X coverage) and 527,754,644 paired-end reads were produced for proband 3 (32.58X coverage).

Sequence Alignment and Annotation

Paired-end reads obtained from sequencing the probands’ whole genomes were aligned to the GRCh37 reference human genome using the Burrows-Wheeler Alignment Tool (BWA) [3]. The resulting SAM files were realigned and recalibrated by implementation of the Genome Analysis Toolkit (GATK) framework [4,5]. Variant calling was performed using the Unified Genotyper tools from GATK. Variant annotation and effect prediction was carried out with SnpEff 3.5a (build 2014-02-14) [6,7] with data from dbSNP Build 138 [8], the 1000 Genomes Project [9], the International HapMap Project [10], the NHGRI GWAS Catalog [11], dbNSFP v2.3 [12,13], the Exome Sequencing Project (ESP) [14], and ClinVar Build 20140211 [15]. See S1 Fig.

Bioinformatic Prioritization of candidate variants (see Table 1)

Only high-quality variants (i.e. not filtered out by the GATK’s Variant Quality Score Recalibration method) were considered for the analysis. Those with recorded population frequencies estimates higher than 1% (data from the 1000 Genomes Project and the Exome Sequencing Project) were also discarded as unlikely to be of relevance. From this remaining set, variants with high probability of affecting gene function (frame-shift, nonsense, missense, affecting splice sites and small insertions and deletions) were grouped according to 3 different models of inheritance that may explain the probands’ phenotype: a recessive model grouped homozygous variants or compound heterozygous candidate variants present in the somatic chromosomes, a X-linked model grouped variants from the X chromosome, and a high impact and rare variants model grouped only high impact (nonsense, frame-shift, splice site changes) variants not recorded in the available databases. These groups were filtered through a list of 182 genes known to be of relevance in ASD according to SFARI database [16] (S1 Table). * Including all changes withing coding regions (synonymous and nonsynonymous substitutions and short insertions and deletions) ** Defined as 2 bases after exon end or 2 bases before exon start (only measured in introns).

Manual Review of Candidate variants

After prioritization, variants considered to possibly explain the phenotype were further investigated individually through the use of several databases and functional evaluation tools which included those provided by NCBI (www.ncbi.nlm.nih.gov), ENSEMBL [17] (www.ensembl.org/index.html), Mutation Taster [18] (www.mutationtaster.org), the Combined Annotation Dependent Depletion framework [19] (cadd.gs.washington.edu) and the Search Tool for the Retrieval of Interacting Genes/Proteins [20] (STRING; string-db.org), among others.

Results

Case Descriptions

Three male siblings were included in this study. All of them presented a syndrome characterized by severe intellectual disability, absence of language, autism spectrum symptoms and epilepsy. Family history was otherwise negative for mental retardation, language disorders, ASD or other psychiatric disorders. They were the sole offspring of healthy and unrelated parents after full-term and uneventful pregnancies (Fig. 1A). The mother performed appropriate health checks during gestations and she didn’t show any pathological findings. Deliveries and birth parameters were unremarkable. The eldest proband (III-1 in Fig. 1A) was symptomatic since birth. Neonatal hypotonia was manifested by sucking difficulties and a mild delay in motor development. He had limited eye contact since 6 months of age. He never developed a functional language. He showed severe behavioral problems, motor stereotypes and circumscribed interests since the age of four. He developed epilepsy at the age of 6, suffering from frequent atonic seizure non-respondent to classical antiepileptic drugs. The younger siblings (III-2 and III-3) showed very similar clinical features. They shared dysmorphic features: broad nasal bridge, bulbous nasal root and macrostomia. They exhibited no neonatal hypotonia and showed normal development during their first two years of life with no observable alterations in language. A progressive deterioration started after this age. Language development was arrested, evolving to an almost complete absence of verbal communication. Social interaction became severely impaired. Agitation and repetitive motor behaviors were present since the age of three. Epilepsy with frequent atonic and generalized seizures refractory to medical treatment started at the age of 7 in both siblings. MRIs were normal and some of the several EEGs done showed right-temporal discharges. Standard karyotype and fragile X testing were normal in the three siblings.
Figure 1

A SHANK3 point mutation in three siblings with Autism Spectrum Disorder.

A) Family pedigree depicting the three probands (III-1, III-2, III-3), parents, their siblings and grandparents. B) Mutation as evidenced by whole genome sequencing compared to reference sequence (GRCh37) at bottom. Broad lines represent aligned reads. The heterozygous deletion is depicted as black, thin lines that interrupt the reads. Each panel depicts the data from one proband, C) Capillary sequencing chromatograms of the probands and their parents. A red arrow signals the position of the deletion. The change in ORF is evidenced by the presence of double peaks after the deletion site caused by heterozygocity. D) Linear representations of the intact SHANK3 protein featuring its major domains and the presumptive protein if translated from the mutated sequence. ANK: ankyrin repeats, SH3: SRC Homology 3 domain, PDZ: PDZ domain, Pro: Proline-rich region, SAM: Sterile alpha motif domain.

A SHANK3 point mutation in three siblings with Autism Spectrum Disorder.

A) Family pedigree depicting the three probands (III-1, III-2, III-3), parents, their siblings and grandparents. B) Mutation as evidenced by whole genome sequencing compared to reference sequence (GRCh37) at bottom. Broad lines represent aligned reads. The heterozygous deletion is depicted as black, thin lines that interrupt the reads. Each panel depicts the data from one proband, C) Capillary sequencing chromatograms of the probands and their parents. A red arrow signals the position of the deletion. The change in ORF is evidenced by the presence of double peaks after the deletion site caused by heterozygocity. D) Linear representations of the intact SHANK3 protein featuring its major domains and the presumptive protein if translated from the mutated sequence. ANK: ankyrin repeats, SH3: SRC Homology 3 domain, PDZ: PDZ domain, Pro: Proline-rich region, SAM: Sterile alpha motif domain.

Whole Genome Analysis

We performed whole genome sequencing of DNA samples from the three siblings, obtaining a mappable yield of 334.1 Gb, which represent an average depth of coverage of 33.04x. We identified more than 4.1 millions of variants in each genome (Table 1). We examined those rare variants (population frequency lower than 1%) in 182 genes associated to ASD (S1 Table) under three possible models of inheritance: recessive, X-linked, high impact de novo mutations (. The most plausible candidate to explain the phenotype exhibited by the probands was a heterozygous deletion of a cysteine in the exon 21 of the SHANK3 gene (Fig. 1, B), resulting in a missense sequence of 5 codons followed by a premature stop codon (NM_033517:c.3259_3259delC, p.Ser1088Profs*6). We did not find any difference in SHANK3 mRNA levels in blood among the three affected siblings, their parents and two unrelated controls, suggesting an absence of effect at the transcription level. Therefore, when expressed this protein would lack a Proline-rich region and the Sterile alpha motif (SAM) domain (Fig. 1, D) resulting in a functional haploinsufficiency of SHANK3 protein. Sanger sequencing confirmed this deletion in the three siblings and their absence in DNA purified from blood samples of both parents suggesting germinal mosaicism as the origin of the mutation (Fig. 1, C).
Table 1

Summary of variants in the 3 genomes.

Proband 1 (III-1) Proband 2 (III-2) Proband 3 (III-3) Shared
Reads 1,150,855,2801,206,005,1361,055,509,288-
High Confidence (HC) Variants 4,157,7294,152,7764,155,1583,153,415
HC Variants in Coding Regions* 24,31923,88223,93918,394
HC Variants at Splice sites ** 467450447351
HC Single Nucleotide Variants (SNV) 3,556,6153,547,6213,543,9942,750,765
HC Short Indels 601,114605,155611,164402,650
HC Variants in ASD gene’s list 71,34869,17369,21553,358
HC Variants compliant to the Recessive Model 438395394145
Genes with HC variants compliant to the Recessive Model 20719819486
HC Variants in in ASD genes and compliant with the Recessive Model 2111
ASD genes with HC Variants compliant with the Recessive Model 2111
HC Variants compliant to the X-Linked Model 1611105
Genes with HC variants compliant to the X-Linked Model 141094
HC Variants in in ASD genes and compliant with the X-Linked Model 1000
ASD genes with HC Variants compliant with the X-Linked Model 1000
HC Variants compliant to the High Impact De Novo Model 2435286
Genes with HC variants compliant to the High Impact De Novo Model 2335276
HC Variants in ASD genes and compliant with the High Impact De Novo Model 1111
ASD genes with HC Variants compliant with the High Impact De Novo Model 1111

* Including all changes withing coding regions (synonymous and nonsynonymous substitutions and short insertions and deletions)

** Defined as 2 bases after exon end or 2 bases before exon start (only measured in introns).

Discussion

Gene mutations can be identified in about 20% of individuals with ASD [21]. SHANK3 aberrations have consistently been associated with idiopathic and syndromic ASD. However, point mutations in SHANK3 have been rarely reported. A few patients were previously described with only one showing familial recurrence. It has been suggested that nonsense and frameshift mutations in this gene lead to more severe phenotypes [22] affecting language and development as it was observed in our patients. Moreover, a recent and exhaustive report on the effect of different mutations in the SHANK family of genes in ASD concluded that SHANK3 mutations are probably the most prevalent etiology of ASD with mental retardation and among the different cases described there it is noteworthy to highlight one that have a frameshift deletion predicted to result in a truncated protein lacking the same functional domains that we predict for our mutation, thereby supporting a pathogenic role for the variant here described, precluding the need for more thorough functional assays [23]. The product of this gene is expressed at postsynaptic densities of excitatory glutamatergic synapses and it is involved in synaptic maturation [24]. Moreover, pharmacological restoring of its deficiency is current object of therapeutic research in ASD [25]. The use of WGS in the clinic is called to be transformative, especially in a complex etiologically heterogeneous disorder such as ASD and intellectual disability [26]. However, recent studies have questioned its readiness for diagnostic adoption mostly because of uncertainties associated with the analysis of such vast amount of information [27]. We have ruled out many variants with a predicted high-impact on protein function because we opted to focus our analysis on genes considered to be of relevance for the phenotype studied therefore decreasing interpretation uncertainties. This left the reported SHANK3 mutation as the sole variant putatively relevant to the phenotype showed in our patients. It is noteworthy to mention that by identifying the pathogenic variant causing the disorder segregating in this family, almost a decade of anxiety associated with diagnostic uncertainties could be alleviated. However, even though we could explain the recurrence of the disorder in the three siblings with the presence of germline mosaicism we could not estimate future recurrence risk because the proportion of germ cells mutated could not be quantified. In summary, we reported an infrequent form of familial ASD where WGS proved useful in the clinic.

Flow diagram of the analysis.

Reads resulting from Whole Genome Sequencing were aligned to the reference genome (GRCh37) with BWA and followed by realignment and recalibration with the Genome Analysis Toolkit (GATK). Variant calling was performed with the Unified Genotyper tool from the GATK, and annotated with SnpEff (see S1 Methods). After the whole variants set was produced, variants shared by the 3 probands were filtered if they presented population frequencies higher than 1% and according to the inheritance models described in Methods. These sets were then filtered by the ASD genes lists (see S1 Table) and manually reviewed for validation. Also, variants resulting from the first filter but not present after the second filter were manually screened and discarded if they showed no relation to the probands phenotype. (TIF) Click here for additional data file. (DOCX) Click here for additional data file.

Candidate genes.

(DOCX) Click here for additional data file.

Inheritance Models.

(DOCX) Click here for additional data file.

High impact High confidence intersection Variants.

(XLSX) Click here for additional data file.
  27 in total

Review 1.  Disentangling the heterogeneity of autism spectrum disorder through genetic findings.

Authors:  Shafali S Jeste; Daniel H Geschwind
Journal:  Nat Rev Neurol       Date:  2014-01-28       Impact factor: 42.937

2.  MutationTaster2: mutation prediction for the deep-sequencing age.

Authors:  Jana Marie Schwarz; David N Cooper; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2014-04       Impact factor: 28.547

3.  dbNSFP v2.0: a database of human non-synonymous SNVs and their functional predictions and annotations.

Authors:  Xiaoming Liu; Xueqiu Jian; Eric Boerwinkle
Journal:  Hum Mutat       Date:  2013-07-10       Impact factor: 4.878

4.  SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients.

Authors:  Aleksandr Shcheglovitov; Olesya Shcheglovitova; Masayuki Yazawa; Thomas Portmann; Rui Shu; Vittorio Sebastiano; Anna Krawisz; Wendy Froehlich; Jonathan A Bernstein; Joachim F Hallmayer; Ricardo E Dolmetsch
Journal:  Nature       Date:  2013-10-16       Impact factor: 49.962

5.  Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift.

Authors:  Pablo Cingolani; Viral M Patel; Melissa Coon; Tung Nguyen; Susan J Land; Douglas M Ruden; Xiangyi Lu
Journal:  Front Genet       Date:  2012-03-15       Impact factor: 4.599

6.  Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments.

Authors:  Claire S Leblond; Caroline Nava; Anne Polge; Julie Gauthier; Guillaume Huguet; Serge Lumbroso; Fabienne Giuliano; Coline Stordeur; Christel Depienne; Kevin Mouzat; Dalila Pinto; Jennifer Howe; Nathalie Lemière; Christelle M Durand; Jessica Guibert; Elodie Ey; Roberto Toro; Hugo Peyre; Alexandre Mathieu; Frédérique Amsellem; Maria Rastam; I Carina Gillberg; Gudrun A Rappold; Richard Holt; Anthony P Monaco; Elena Maestrini; Pilar Galan; Delphine Heron; Aurélia Jacquette; Alexandra Afenjar; Agnès Rastetter; Alexis Brice; Françoise Devillard; Brigitte Assouline; Fanny Laffargue; James Lespinasse; Jean Chiesa; François Rivier; Dominique Bonneau; Beatrice Regnault; Diana Zelenika; Marc Delepine; Mark Lathrop; Damien Sanlaville; Caroline Schluth-Bolard; Patrick Edery; Laurence Perrin; Anne Claude Tabet; Michael J Schmeisser; Tobias M Boeckers; Mary Coleman; Daisuke Sato; Peter Szatmari; Stephen W Scherer; Guy A Rouleau; Catalina Betancur; Marion Leboyer; Christopher Gillberg; Richard Delorme; Thomas Bourgeron
Journal:  PLoS Genet       Date:  2014-09-04       Impact factor: 5.917

7.  An integrated map of genetic variation from 1,092 human genomes.

Authors:  Goncalo R Abecasis; Adam Auton; Lisa D Brooks; Mark A DePristo; Richard M Durbin; Robert E Handsaker; Hyun Min Kang; Gabor T Marth; Gil A McVean
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

8.  SHANK3 haploinsufficiency: a "common" but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders.

Authors:  Catalina Betancur; Joseph D Buxbaum
Journal:  Mol Autism       Date:  2013-06-11       Impact factor: 7.509

9.  Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants.

Authors:  Wenqing Fu; Timothy D O'Connor; Goo Jun; Hyun Min Kang; Goncalo Abecasis; Suzanne M Leal; Stacey Gabriel; Mark J Rieder; David Altshuler; Jay Shendure; Deborah A Nickerson; Michael J Bamshad; Joshua M Akey
Journal:  Nature       Date:  2012-11-28       Impact factor: 49.962

10.  ClinVar: public archive of relationships among sequence variation and human phenotype.

Authors:  Melissa J Landrum; Jennifer M Lee; George R Riley; Wonhee Jang; Wendy S Rubinstein; Deanna M Church; Donna R Maglott
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

View more
  22 in total

Review 1.  The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.

Authors:  Davide Mei; Elena Parrini; Carla Marini; Renzo Guerrini
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

2.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-05-28       Impact factor: 6.186

3.  Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review.

Authors:  Jordi Soler; Lourdes Fañanás; Mara Parellada; Marie-Odile Krebs; Guy A Rouleau; Mar Fatjó-Vilas
Journal:  J Psychiatry Neurosci       Date:  2018-07       Impact factor: 6.186

4.  2014 Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across The Lifespan.

Authors:  Alica M Goldman; W Curt LaFrance; Tim Benke; Miya Asato; Dan Drane; Alison Pack; Tanvir Syed; Robert Doss; Samden Lhatoo; Brandy Fureman; Ray Dingledine
Journal:  Epilepsy Curr       Date:  2016 May-Jun       Impact factor: 7.500

5.  Post-zygotic Point Mutations Are an Underrecognized Source of De Novo Genomic Variation.

Authors:  Rocio Acuna-Hidalgo; Tan Bo; Michael P Kwint; Maartje van de Vorst; Michele Pinelli; Joris A Veltman; Alexander Hoischen; Lisenka E L M Vissers; Christian Gilissen
Journal:  Am J Hum Genet       Date:  2015-06-06       Impact factor: 11.025

6.  Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Kandamurugu Manickam; Monica R McClain; Laurie A Demmer; Sawona Biswas; Hutton M Kearney; Jennifer Malinowski; Lauren J Massingham; Danny Miller; Timothy W Yu; Fuki M Hisama
Journal:  Genet Med       Date:  2021-07-01       Impact factor: 8.822

7.  Variability in Phelan-McDermid Syndrome in a Cohort of 210 Individuals.

Authors:  Julián Nevado; Sixto García-Miñaúr; María Palomares-Bralo; Elena Vallespín; Encarna Guillén-Navarro; Jordi Rosell; Cristina Bel-Fenellós; María Ángeles Mori; Montserrat Milá; Miguel Del Campo; Pilar Barrúz; Fernando Santos-Simarro; Gabriela Obregón; Carmen Orellana; Harry Pachajoa; Jair Antonio Tenorio; Enrique Galán; Juan C Cigudosa; Angélica Moresco; César Saleme; Silvia Castillo; Elisabeth Gabau; Luis Pérez-Jurado; Ana Barcia; Maria Soledad Martín; Elena Mansilla; Isabel Vallcorba; Pedro García-Murillo; Franco Cammarata-Scalisi; Natálya Gonçalves Pereira; Raquel Blanco-Lago; Mercedes Serrano; Juan Dario Ortigoza-Escobar; Blanca Gener; Verónica Adriana Seidel; Pilar Tirado; Pablo Lapunzina
Journal:  Front Genet       Date:  2022-04-12       Impact factor: 4.772

8.  Case report: an unexpected link between partial deletion of the SHANK3 gene and Heller's dementia infantilis, a rare subtype of autism spectrum disorder.

Authors:  Anne Philippe; Yann Craus; Marlène Rio; Nadia Bahi-Buisson; Nathalie Boddaert; Valérie Malan; Jean-Paul Bonnefont; Laurence Robel
Journal:  BMC Psychiatry       Date:  2015-10-21       Impact factor: 3.630

Review 9.  Genetics of Autism Spectrum Disorder: Current Status and Possible Clinical Applications.

Authors:  Heejeong Yoo
Journal:  Exp Neurobiol       Date:  2015-12-16       Impact factor: 3.261

Review 10.  Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3.

Authors:  Shigeo Uchino; Chikako Waga
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.